Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 14/20 | 0.58 |
| ▸ | LIG1 | P18858 | 1/20 | 0.57 |
| ▸ | TAAR5 | O14804 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005004 | 0.81 | PCNA (0.66) | PCNALIG1TAAR5TAAR1 | |
| SCHEMBL16124480 | 0.81 | PCNA (0.63) | PCNALIG1TAAR5TAAR1 | |
| SCHEMBL14485265 | 0.80 | PCNA (0.64) | PCNALIG1TAAR5TAAR1 | |
| SCHEMBL5743343 | 0.79 | PCNA (0.62) | PCNALIG1 | |
| SCHEMBL13886598 | 0.77 | TAAR5 (0.68) | PCNALIG1TAAR5TAAR1 | |
| SCHEMBL22382794 | 0.77 | PCNA (0.67) | PCNALIG1TAAR5TAAR1 | |
| SCHEMBL14264010 | 0.77 | PCNA (0.67) | PCNALIG1TAAR5TAAR1 | |
| SCHEMBL14230070 | 0.77 | PCNA (0.62) | PCNALIG1 | |
| SCHEMBL21500873 | 0.77 | PCNA (0.57) | PCNALIG1 | |
| SCHEMBL5742613 | 0.76 | PCNA (0.74) | PCNALIG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383736-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1383736-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6967220-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-22 | — | — | US | disclosed |
| US-20040106795-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-06-03 | — | — | US | disclosed |
| EP-1383736-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003002522-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106795-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | PCNA 1541/4885LIG1 2800/4885TAAR5 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.